""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

FAculty directory

Back to alphabetical index

 

Satoru Eguchi, MD, PhDSatoru Eguchi, MD, PhD

 

Professor, Physiology

Professor, Cardiovascular Research Center

Professor, Sol Sherry Thrombosis Research Center

Telephone:  215-707-0169

Fax:  215-707-5737

Office: MERB 1051

Email: seguchi@temple.edu

 

Department of Physiology

Cardiovascular Research Center

Sol Sherry Thrombosis Research Center

 

Educational Background:

 

MD, Tohoku University School of Medicine, Sendai, Japan, 1987

 

PhD, Tokyo Medical and Dental University, Tokyo, Japan, 1993

 

Fellowship, Vanderbilt University School of Medicine, Nashville, TN, 1994

Return to top

 

 

Research Interests:

 

Satoru Eguchi MD PhD FAHA started his academic career as a physician scientist in Japan concentrating on cardiovascular endocrinology in 1989. His research has been specifically focused on cardiovascular GPCR signal transduction and its functional significance linked to cardiovascular diseases. In 1994, he joined the lab of Dr. Tadashi Inagami (Vanderbilt University), a highly recognized scientist in the area of renin-angiotensin research. After gaining invaluable experience, Dr. Eguchi successfully completed his postdoctoral training in 1996. His J Biol Chem (273:8890-6, 1998) publication with Dr. Inagami regarding the EGF receptor transactivation mechanism by angiotensin II (Ang II) in cultured vascular smooth muscle cells (VSMCs) has been sited more than 400 times, which helped him become independent and obtain extramural funds. Since then, Dr. Eguchi and his research group have been recognized as one of the leading authorities of Ang II signal transduction and the functions linked to vascular pathophysiology.

 

He has been a member of several American Heart Association (AHA) Study sections including co-chair (Endothelial Biology), and Ad hoc member of several study sections of the National Institutes of Health (NIH) in the USA. He has been funded by grants from NIH and the AHA. He is also a recipient of the AHA National Established Investigator Award (2006). He is currently Associate Editor of Clinical Science and an editorial board member of several high impact journals including Circulation Research, Arteriosclerosis Thrombosis and Vascular Biology, Hypertension, American Journal of Physiology (Cell Physiology & Heart Circulation), and American Journal of Hypertension. He was recently selected as a Superior Editorial Consultant (Circulation Research 2010 & 2011) and the Top 5 reviewers (Hypertension 2011-2013). He has published over 120 original papers and many review articles and editorials. His current focus of research relates to molecular, cellular and vascular mechanisms of pathophysiological vascular remodeling. He has a particular interest in the cardiovascular signaling mechanisms and their translational aspects.

 

The renin-angiotensin-aldosterone system is recognized as one of the most important research targets in cardiovascular pathophysiology. Notably, Dr. Eguchi has created a novel and fundamental research program to study the molecular mechanisms of the EGF receptor transactivation by AngII together with its significance in mediating cardiovascular remodeling. Also, his research group is especially talented at manipulating the AngII/GPCR-linked key signaling molecules with multiple applications of molecular biology tools, both in vitro with primary culture and in vivo with rodent vasculature. This approach has yielded seminal discoveries of potential target molecules and their detailed molecular mechanisms in mediating vascular remodeling. Moreover at the CVRC with Dr. Rizzo, Dr. Scalia and Dr. Autieri as key collaborators, his research includes in vivo analysis of the AngII signal transduction using adenoviral mediated gene transfer as well as Ang II infusion to the mice for evaluation of hypertension and associated vascular damage in multiple organs including abdominal aortic aneurysm (AAA).

 

The Eguchi lab employs three different research strategies. 1) Eguchi lab creates viral and non-viral expression vectors including miRNA based-gene silencing and mutagenesis. Creation of tissue-specific viral vectors for translational research is also ongoing. 2) Eguchi lab is famous for its excellent cell biology/signal transduction research using primary cultured vascular cells and advanced techniques for signal transduction research. 3) Eguchi lab is actively working on animal experiments using tissue-specific gene knockout mice such as sm22alpha (SMC) Cre-driver mice where vascular ADAM17 (an upstream metalloprotease for EGFR activation) or EGFR is silenced. Cardiovascular pathophysiology is induced in mice with osmotic mini-pump infusion of Ang II to induce organ damage (vascular and cardiac hypertrophy and cardiac and renal fibrosis) and AAA. In addition, surgery such as carotid artery partial ligation is performed to induce disturbed flow-mediated vascular inflammation and hyperplasia.

 

Eguchi lab is regarded as one of the top labs in TUSM in terms of training, publishing, and research. Potential students and fellows can expect to learn balanced research strategies, use up to date methodologies for experimentation and project management, and be guided into key research directions from a dedicated and experienced mentor and senior fellows.

 

research interests

Ang II induces ADAM17 expression and vascular EGFR activation via HIF-1 (Obama T, Eguchi S: 2014).

 

 

research interests

Replacement of endogenous ADAM17 with mutants using adenovirus encoding ADAM17 mi/siRNA (Elliott KJ, Eguchi S: 2013).

 

 

research interests

Ang II-induced AAA formation was attenuated in Cav1-/- mice ( Takayanagi T, Eguchi S: 2014).

 

Return to top

 

 

PUBMED PUBLICATIONS :


Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

25064430. Obama T, Eguchi S, MicroRNA as a novel component of the tissue renin angiotensin system. J Mol Cell Cardiol 75:(98-9)2014 Oct

24871629. Obama T, Takayanagi T, Kobayashi T, Bourne AM, Elliott KJ, Charbonneau M, Dubois CM, Eguchi S, Vascular Induction of a Disintegrin and Metalloprotease 17 by Angiotensin II Through Hypoxia Inducible Factor 1a. Am J Hypertens 28:1(10-4)2015 Jan

24814101. Ellison S, Gabunia K, Richards JM, Kelemen SE, England RN, Rudic D, Azuma YT, Munroy MA, Eguchi S, Autieri MV, IL-19 reduces ligation-mediated neointimal hyperplasia by reducing vascular smooth muscle cell activation. Am J Pathol 184:7(2134-43)2014 Jul

24711521. Obama T, Scalia R, Eguchi S, Targeting neutrophil: new approach against hypertensive cardiac remodeling? Hypertension 63:6(1171-2)2014 Jun

24483935. Obama T, Eguchi S, Integrin-linked kinase: a new member of the kinases involved in hypertensive end-organ damage? Clin Sci (Lond) 127:1(15-7)2014 Jul

24401846. Deliu E, Brailoiu GC, Eguchi S, Hoffman NE, Rabinowitz JE, Tilley DG, Madesh M, Koch WJ, Brailoiu E, Direct evidence of intracrine angiotensin II signaling in neurons. Am J Physiol Cell Physiol 306:8(C736-44)2014 Apr 15

24329494. Takayanagi T, Crawford KJ, Kobayashi T, Obama T, Tsuji T, Elliott KJ, Hashimoto T, Rizzo V, Eguchi S, Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase. Clin Sci (Lond) 126:11(785-94)2014 Jun

23688779. Elliott KJ, Bourne AM, Takayanagi T, Takaguri A, Kobayashi T, Eguchi K, Eguchi S, ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells. J Mol Cell Cardiol 62:(1-7)2013 Sep

23535568. Takayanagi T, Eguchi A, Takaguri A, Hinoki A, Bourne AM, Elliott KJ, Hurlin PJ, Eguchi S, A repressor protein, Mnt, is a novel negative regulator of vascular smooth muscle cell hypertrophy by angiotensin II and neointimal hyperplasia by arterial injury. Atherosclerosis 228:1(90-3)2013 May

22113169. Takayanagi T, Bourne AM, Kimura K, Takaguri A, Elliott KJ, Eguchi K, Eguchi S, Constitutive stimulation of vascular smooth muscle cells by angiotensin II derived from an adenovirus encoding a furin-cleavable fusion protein. Am J Hypertens 25:3(280-3)2012 Mar

21927009. Bourne AM, Eguchi S, Angiotensin II causes vascular smooth muscle insulin resistance: attractive mechanism but more to clarify. Am J Hypertens 24:10(1057-8)2011 Oct

21357274. Takaguri A, Kimura K, Hinoki A, Bourne AM, Autieri MV, Eguchi S, A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature. Hypertension 57:4(841-5)2011 Apr

21172357. Takaguri A, Shirai H, Kimura K, Hinoki A, Eguchi K, Carlile-Klusacek M, Yang B, Rizzo V, Eguchi S, Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II. J Mol Cell Cardiol 50:3(545-51)2011 Mar

21071702. Smolock AR, Mishra G, Eguchi K, Eguchi S, Scalia R, Protein kinase C upregulates intercellular adhesion molecule-1 and leukocyte-endothelium interactions in hyperglycemia via activation of endothelial expressed calpain. Arterioscler Thromb Vasc Biol 31:2(289-96)2011 Feb

20929813. Wang Y, Deng X, Mancarella S, Hendron E, Eguchi S, Soboloff J, Tang XD, Gill DL, The calcium store sensor, STIM1, reciprocally controls Orai and CaV1.2 channels. Science 330:6000(105-9)2010 Oct 1

19901155. Hinoki A, Kimura K, Higuchi S, Eguchi K, Takaguri A, Ishimaru K, Frank GD, Gerthoffer WT, Sommerville LJ, Autieri MV, Eguchi S, p21-activated kinase 1 participates in vascular remodeling in vitro and in vivo. Hypertension 55:1(161-5)2010 Jan

19095998. Suzuki H, Kimura K, Shirai H, Eguchi K, Higuchi S, Hinoki A, Ishimaru K, Brailoiu E, Dhanasekaran DN, Stemmle LN, Fields TA, Frank GD, Autieri MV, Eguchi S, Endothelial nitric oxide synthase inhibits G12/13 and rho-kinase activated by the angiotensin II type-1 receptor: implication in vascular migration. Arterioscler Thromb Vasc Biol 29:2(217-24)2009 Feb

19064814. Suzuki H, Motley ED, Eguchi K, Hinoki A, Shirai H, Watts V, Stemmle LN, Fields TA, Eguchi S, Distinct roles of protease-activated receptors in signal transduction regulation of endothelial nitric oxide synthase. Hypertension 53:2(182-8)2009 Feb

18779232. Sommerville LJ, Xing C, Kelemen SE, Eguchi S, Autieri MV, Inhibition of allograft inflammatory factor-1 expression reduces development of neointimal hyperplasia and p38 kinase activity. Cardiovasc Res 81:1(206-15)2009 Jan 1

18356277. Ohtsu H, Higuchi S, Shirai H, Eguchi K, Suzuki H, Hinoki A, Brailoiu E, Eckhart AD, Frank GD, Eguchi S, Central role of Gq in the hypertrophic signal transduction of angiotensin II in vascular smooth muscle cells. Endocrinology 149:7(3569-75)2008 Jul

18180404. Nakashima H, Frank GD, Shirai H, Hinoki A, Higuchi S, Ohtsu H, Eguchi K, Sanjay A, Reyland ME, Dempsey PJ, Inagami T, Eguchi S, Novel role of protein kinase C-delta Tyr 311 phosphorylation in vascular smooth muscle cell hypertrophy by angiotensin II. Hypertension 51:2(232-8)2008 Feb

17346243. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S, Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112:8(417-28)2007 Apr

17293685. Shirai H, Autieri M, Eguchi S, Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 16:2(111-5)2007 Mar

17080158. Suzuki H, Eguchi S, Adiponectin versus angiotensin II: Key pathological role of their misbalance. Kidney Int 70:10(1678-9)2006 Nov

16980435. Suzuki H, Eguchi K, Ohtsu H, Higuchi S, Dhobale S, Frank GD, Motley ED, Eguchi S, Activation of endothelial nitric oxide synthase by the angiotensin II type 1 receptor. Endocrinology 147:12(5914-20)2006 Dec

16923993. Ohtsu H, Suzuki H, Nakashima H, Dhobale S, Frank GD, Motley ED, Eguchi S, Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 48:4(534-40)2006 Oct

16840716. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S, ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 26:9(e133-7)2006 Sep

16769815. Ohtsu H, Dempsey PJ, Eguchi S, ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291:1(C1-10)2006 Jul

16724941. Suzuki H, Frank GD, Utsunomiya H, Higuchi S, Eguchi S, Current understanding of the mechanism and role of ROS in angiotensin II signal transduction. Curr Pharm Biotechnol 7:2(81-6)2006 Apr

16472178. Nakashima H, Suzuki H, Ohtsu H, Chao JY, Utsunomiya H, Frank GD, Eguchi S, Angiotensin II regulates vascular and endothelial dysfunction: recent topics of Angiotensin II type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol 4:1(67-78)2006 Jan

16250862. Suzuki H, Motley ED, Frank GD, Utsunomiya H, Eguchi S, Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents 3:4(305-22)2005 Oct

16115037. Ohtsu H, Frank GD, Utsunomiya H, Eguchi S, Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology. Antioxid Redox Signal 7:9-10(1315-26)2005 Sep-Oct

15998260. Frank GD, Eguchi S, Motley ED, The role of reactive oxygen species in insulin signaling in the vasculature. Antioxid Redox Signal 7:7-8(1053-61)2005 Jul-Aug

15994438. Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, Kim-Mitsuyama S, Takuwa Y, Sasaki T, Rothstein JD, Suzuki H, Nakashima H, Woolfolk EA, Motley ED, Eguchi S, Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol 25:9(1831-6)2005 Sep

15905175. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S, G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 280:28(26592-9)2005 Jul 15

15163624. Mifune M, Ohtsu H, Suzuki H, Frank GD, Inagami T, Utsunomiya H, Dempsey PJ, Eguchi S, Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. Am J Physiol Cell Physiol 287:3(C807-13)2004 Sep

14641025. Eguchi S, Frank GD, Mifune M, Inagami T, Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem Soc Trans 31:Pt 6(1198-202)2003 Dec

14588150. Frank GD, Eguchi S, Activation of tyrosine kinases by reactive oxygen species in vascular smooth muscle cells: significance and involvement of EGF receptor transactivation by angiotensin II. Antioxid Redox Signal 5:6(771-80)2003 Dec

12588978. Frank GD, Mifune M, Inagami T, Ohba M, Sasaki T, Higashiyama S, Dempsey PJ, Eguchi S, Distinct mechanisms of receptor and nonreceptor tyrosine kinase activation by reactive oxygen species in vascular smooth muscle cells: role of metalloprotease and protein kinase C-delta. Mol Cell Biol 23:5(1581-9)2003 Mar

12226102. Saito S, Frank GD, Mifune M, Ohba M, Utsunomiya H, Motley ED, Inagami T, Eguchi S, Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and c-Src. J Biol Chem 277:47(44695-700)2002 Nov 22

12074579. Saito S, Frank GD, Motley ED, Dempsey PJ, Utsunomiya H, Inagami T, Eguchi S, Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 294:5(1023-9)2002 Jun 28

12044791. Saito S, Frank GD, Motley ED, Utsunomiya H, Inagami T, Eguchi S, Cyclosporin A inhibits angiotensin II-induced c-Jun NH(2)-terminal kinase activation but not protein synthesis in vascular smooth muscle cells. Eur J Pharmacol 443:1-3(47-50)2002 May 17

11818507. Frank GD, Saito S, Motley ED, Sasaki T, Ohba M, Kuroki T, Inagami T, Eguchi S, Requirement of Ca(2+) and PKCdelta for Janus kinase 2 activation by angiotensin II: involvement of PYK2. Mol Endocrinol 16:2(367-77)2002 Feb

11520052. Frank GD, Eguchi S, Motley ED, Sasaki T, Inagami T, Unique regulation of c-Jun N-terminal kinase by PYK2/CAK-beta in angiotensin II-stimulated vascular smooth muscle cells. Biochem Biophys Res Commun 286:4(692-6)2001 Aug 31

11116149. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T, Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276:11(7957-62)2001 Mar 16

10967198. Eguchi S, Inagami T, Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept 91:1-3(13-20)2000 Jul 28

10829089. Inagami T, Eguchi S, Angiotensin II-mediated vascular smooth muscle cell growth signaling. Braz J Med Biol Res 33:6(619-24)2000 Jun

10772898. Frank GD, Motley ED, Inagami T, Eguchi S, PYK2/CAKbeta represents a redox-sensitive tyrosine kinase in vascular smooth muscle cells. Biochem Biophys Res Commun 270:3(761-5)2000 Apr 21

10601235. Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, Marumo F, Hirata Y, Inagami T, Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem 274:52(36843-51)1999 Dec 24

10440105. Eguchi S, Iwasaki H, Hirata Y, Frank GD, Motley ED, Yamakawa T, Numaguchi K, Inagami T, Epidermal growth factor receptor is indispensable for c-Fos expression and protein synthesis by angiotensin II. Eur J Pharmacol 376:1-2(203-6)1999 Jul 2

Return to top

 

 

laboratory personnel:

 

Kunie Eguchi

Senior Laboratory Technician

T:  215-707-8378

F:  215-707-5737

Email address: kunie.eguchi@temple.edu

 

Kathy Elliott

Research Associate II

Email address: kelliott@temple.edu

 

Return to top